There was no reported device malfunction and the device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effects of ischemia, occlusion and thrombosis are listed in the biomimics 3d instructions for use and are known patient effects of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available a follow-up report will be submitted.
|
The patient was treated as part of the mimics-3d european post-market observational study on (b)(6) 2018.At index procedure (((b)(6) 2018), the patient presented with a de-novo occlusion of the segment involving the middle third of the superficial femoral artery (sfa) and the distal third of the sfa of the left leg.One 6.0 x 125mm biomimics stent was implanted.On (b)(6) 2019 an event of ischemia was reported.This event was not related to the device or the procedure but was described as an intercurrent intervention.Percutaneous intervention took place on the (b)(6) 2019 and involved bare metal stent, drug coated balloon / drug eluting balloon and percutaneous transluminal angioplasty /standard balloon angioplasty and thrombolysis of the segment between the middle third of the sfa and distal popliteal artery.The outcome of the event is that it has resolved and patient has recovered.The device remains implanted.
|